Jane Street Group, LLC Arrowhead Pharmaceuticals, Inc. Put Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 17, 2022	SELL	$39.62 - $69.97 $324,884 - $573,754	-8,200 Reduced 13.02%	54,800 $2.52 Million
Q4 2021 Feb 15, 2022	SELL	$58.09 - $82.51 $162,652 - $231,028	-2,800 Reduced 4.26%	63,000 $4.18 Million
Q3 2021 Nov 16, 2021	BUY	$58.38 - $84.96 $1.06 Million - $1.54 Million	18,100 Added 37.95%	65,800 $4.11 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $2.1 Million - $3.05 Million	33,800 Added 243.17%	47,700 $3.95 Million
Q1 2021 May 18, 2021	SELL	$61.35 - $90.47 $1.74 Million - $2.56 Million	-28,300 Reduced 67.06%	13,900 $922,000

Q4 2020 Feb 17, 2021	SELL	$43.82 - $85.37 $2.29 Million - $4.46 Million	-52,300 Reduced 55.34%	42,200 $3.24 Million
Q3 2020 Nov 17, 2020	BUY	$33.21 - $51.27 $275,643 - $425,541	8,300 Added 9.63%	94,500 $4.07 Million
Q2 2020 Aug 17, 2020	BUY	$26.12 - $43.27 $1.54 Million - $2.55 Million	58,900 Added 215.75%	86,200 $3.72 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $273,448 - $839,496	-13,300 Reduced 32.76%	27,300 $785,000
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $1.14 Million - $2.96 Million	40,600 New	40,600 $2.58 Million

296

88.5M

905K

387K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.